Recombinant human granulocyte colony-stimulating factors (G-CSFs) are the only currently available agents that are used for mobilisation of peripheral blood stem cells (PBSCs) and their subsequent infusion.
collection level of >3x10 6 CD34 + /kg bodyweight in two leukaphereses. 10 Ataergin et al. showed in a randomised study that filgrastim 10µg/kg/day and lenograstim 7.5µg/kg/day resulted in successful mobilisation of CD34 + cells in patients undergoing high-dose chemotherapy (HDC) and PBSC transplantation. Successful mobilisation with the first apheresis was achieved in 10 of 20 patients (50%) in the filgrastim group versus nine of 20 patients (46%) in the lenograstim group. No significant difference was seen in the median number of CD34 + cells mobilised, the median number of aphereses, the median volume of apheresis, the percentage of CD34 + cells or CD34 + cell number. This study showed that lenograstim at a 25% lower dose does not negatively affect the number of CD34 + stem cells harvested. to assess the mobilising efficacy of filgrastim, lenograstim and molgramostim. Following a disease-specific chemotherapy regimen, randomisation to filgrastim, lenograstim or molgramostim at 5μg/kg/day was performed. The median number of CD34 + cells obtained after mobilisation was 8.4x10 6 /kg in the filgrastim arm versus 5.8x10 6 /kg in the lenograstim arm versus 4.0x10 6 /kg in the molgramostim arm (p=0.1).
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All three growth factors were efficacious in mobilising peripheral stem cells, with no statistically significant difference.
13
Another prospective randomised study, by Karanth et al., compared the efficiency of PBSC mobilisation using either cyclophosphamide (2g/m²) and lenograstim at 5μg/kg (n=39) or lenograstim alone at 10μg/kg (n=40 Haematological Malignancies beneficial for stem cell transplantation patients, and further studies should be carried out. Another prospective randomised study, conducted by Öztürk et al., compared patients undergoing APSCT and mobilisation with a low dose (7.5µg/kg/day) or a standard dose (10µg/kg/day) of lenograstim.
Studies with Lenograstim on Post-transplant Engraftment for Autologous Transplantation
In the post-transplant period, lenograstim was given at 5µg/kg/day for both groups until leukocyte engraftment. Leukocyte and platelet engraftments, parenteral antibiotics and the number of transfusions were similar in both groups in the post-transplant period. 
